Tafnat 25mg (Tenofovir Alafenamide -TAF) 25mg

Hello, this is Tafnat
Epidemiology and Disease Burden
Transmission and Virology
Disease Course and Diagnosis of Chronic Hepattis B Virus Infection
SHOP NOW

Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF)

TAFNAT 25mg

Hepatitis B Virus: Disease Background of Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) 25mg Tablet

  • Epidemiology and Disease Burden
  • Transmission and Virology
  • Disease Course and Diagnosis of Chronic Hepatitis B Virus Infection
  • Compensated Cirrhosis and Decompensated Cirrhosis with Chronic Hepatitis B 8
  • Hepatocellular Carcinoma/Liver Transplantation
  • Co-infections with Hepatitis
  • New Perspective on Treatment of Patients with Hepatitis B Infection.

Spotlight onTafnat 25mg (Tenofovir Alafenamide -TAF)- Tenofovir Alafenamide Fumarate :
As a Newer Treatment Modality in Hepatitis B infection.

Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) 25mg Tablet Preface :


Chronic infection with Hepatitis B Virus (HBV) constitutes a major global public health problem despite the availability of a prophylactic vaccine.
Hepatitis B infections are the notable causes for disease burden such as liver cirrhosis and Hepatocellular Carcinoma (HCC) .
Tafnat 25mg (Tenofovir Alafenamide -TAF) tablets diagnosis of HBV infections and its associated 2 diseases are mainly based on a constellation of clinical, biochemical, histological and serological findings. The persistence of serum Hepatitis B.
Tafnat 25mg (Tenofovir Alafenamide -TAF) 25mg (Tenofovir Alafenamide) is added as a new drug to the list of recommendations for the treatment of CHB.
Tafnat 25mg (Tenofovir Alafenamide -TAF) Tablets (TAF has) pharmacology similar to TDF with a higher cell delivery to hepatocytes but less systemic exposure.
“FDA has approved Tafnat 25mg (Tenofovir alafenamide -TAF) (tenofovir alafenamide) once daily for the treatment of chronic HBV infection in adults with compensated liver disease”.

Mechanism of Action :


Tafnat 25mg (Tenofovir Alafenamide -TAF) 25mg (TAF) is a Nucleotide Reverse Transcriptase Inhibitor (NRTI) and a novel ester prodrug of the antiretroviral,tenofovir.
Following oral administration, Tafnat 25mg (Tenofovir alafenamide -TAF) (TAF) is converted in vivo to tenofovir. An acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Tenofovir alafenamide 25mg Tablets mimics normal DNA building blocks but is lacking a 3'-OH molecule required for phosphodiester bond linkage.
A competing TAF with regular nucleotides for incorporation into the proviral DNA and prevention of the formation of 5 to 3 tenofovir tablets. A phosphodiester linkage required for DNA elongation.
Tafnat 25mg (Tenofovir Alafenamide -TAF) tablets causes early chain termination and prevents proviral DNA 27 transcription.

Pharmacokinetics :

The Pharmacokinetic properties of Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) 25mg (TAF) are given below. The multiple dose PK parameters of Tafnat 25mg (Tenofovir alafenamide -TAF) 25mg Tablet (TAF) and 28 its metabolite, Tenofovir,are provided in Table 3.

Tafnat Bio availability :

Tafant 25mg following oral administration, peak plasma concentrations occur approximately 0.48 hours after the dose.

Food :

Administration of a high-fat meal increases Area Under Curve (AUC) by 1.65 folds compared with administration 28 in the fasting state.

Distribution:

Plasma protein binding is 80%.

Metabolism of Tafnat 25mg (Tenofovir alafenamide -TAF) :

Tafnat 25mg (Tenofovir alafenamide -TAF) requires initial hydrolysis for intracellular conversion to tenofovir and subsequent phosphorylation by cellular enzymes to form the active metabolite, tenofovir diphosphate.
Tafnat first hydrolyzed in hepatocytes and cathepsin A in Peripheral Blood Mononuclear Cells (PBMCs) and macrophages BY THE METHOD OF intracellular , Carboxylesterase 1 (CES1)
Tafnat 25mg (Tenofovir alafenamide -TAF) tablet Only minimally metabolized by CYP3A.

Contraindications:

There are no contraindication reported with Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF)

TAFNAT Warnings and Precautions :

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues. Treatment with Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity .

Post Treatment Exacerbation of Hepatitis B Infection :

Discontinuation of Tafnat25mg (Tenofovir Alafenamide Fumarate -TAF) may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue of (Tenofovir alafenamide -TAF) tablets.

Risk of Development of HIV-1 Resistance in Patients Co-infected with HBV and HIV-1 :

Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) alone is not recommended for the treatment of HIV-1 infection, as there is a risk of development of HIV-1 resistance. In patients co-infected with HBV and HIV-1, efficacy of TAF has not been established. Prior to initiating the therapy with Tafnat 25mg (Tenofovir Alafenamide -TAF) in patients with HBV-HIV co-infected patients, HIV antibody testing should be offered and, if positive, an appropriate antiretroviral combination regimen that is recommended for patients coinfected with HIV-1 should be used.

Indications and Usage :

Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) is indicated for the treatment of chronic HBV infection in adults with compensated liver disease.
Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) Tablet Dosage Forms and Composition :
Composition: Each Tafnat 25mg (Tenofovir Alafenamide Fumarate -TAF) tablet contains 25 mg of tenofovir alafenamide WHICH IS equivalent to 28 mg of Tenofovir Alafenamide Fumarate).
Tafnat 25mg (Tenofovir alafenamide -TAF) tablet includes the following inactive ingredients.
Croscarmellose sodium,lactose monohydrate, magnesium stearate and microcrystalline cellulose.
Tafnat 25mg (Tenofovir alafenamide -TAF) tablet is film coated with a coating material containing. Iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium 28 dioxide.

Storage and Handling :

• 28 Store below 30°C (86°F).
• Keep container tightly closed.
• Dispense only in original container.

TAFNAT

Bio availability :

Tafant 25mg following oral administration, peak plasma concentrations occur approximately 0.48 hours after the dose.

Food :

Administration of a high-fat meal increases Area Under Curve (AUC) by 1.65 folds compared with administration 28 in the fasting state.

Contraindications:

There are no contraindication reported withTafnat 25mg (Tenofovir alafenamide -TAF)

Prescription

tafnat.com is a fully licensed and regulated pharmacy, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

tafnat.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists

The drug information provided in the tafnat.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

tafnat.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from tafnat.com

tafnat.com is a Caregiver can order prescription medicines on your behalf.

Disclaimer

This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.

CONTACT US

TAFNAT

Tafnat (Tenofovir Alafenamide -TAF) 25mg Tablet Brand Name: Tafnat
Composition: Tenofovir Alafenamide (TAF) 25mg
Packing: Pack of 30 Tablets

Chronic infection with Hepatitis B Virus (HBV) constitutes a major global public health problem despite the availability of a prophylactic vaccine.
Hepatitis B infections are the notable causes for disease burden such as liver cirrhosis and Hepatocellular Carcinoma (HCC) .

OUR ADDRESS

WE CAN HELP YOU

+91 - 99404 72902

millionhealthpharmaceuticals@gmail.com
                   info@tafnat.com

Pedariyar Kovil Street, Seven Wells,
                 Chennai - 600 001. Tamilnadu, India.